Physician profile
Matthew M Bender
NPI 1881633162
$3,069.43
in general payments reported to CMS, 2019-2025
30 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $93.71 · 2021: $40.23 · 2022: $427 · 2023: $389 · 2024: $137 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,300 · Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,300.00 |
| Food and Beverage | $726.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,380.78 | 2023-2025 | Bimzelx |
| Pfizer INC. | $313.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $156.82 | 2019-2023 | |
| Lilly USA, LLC | $124.37 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $115.94 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $100.17 | 2023-2025 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $86.52 | 2019 | |
| Novo Nordisk INC | $85.82 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $76.82 | 2023-2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.88 | 2019-2023 | Xifaxan |
| Leo Pharma INC. | $66.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $63.66 | 2019-2020 | |
| Dexcom, INC. | $56.69 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $51.62 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Philips North America LLC | $38.43 | 2019-2025 | Wearables Biosensors |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $33.75 | 2019 | |
| Organon LLC | $29.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $25.26 | 2025 | Recorlev |
| E.R. Squibb & Sons, L.L.C. | $22.24 | 2019 | |
| Incyte Corporation | $19.34 | 2022 | |
| Abbvie INC. | $18.75 | 2019 | |
| Mylan Specialty L.P. | $16.95 | 2024 | Yupelri |
| Celgene Corporation | $16.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.63 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.11 | 2020 | |
| Glaxosmithkline, LLC. | $16.05 | 2022 | |
| Sonex Health, INC. | $15.22 | 2025 | Sx-One Microknife |
| Janssen Biotech, INC. | $13.39 | 2024 | Tremfya |
| Upsher-Smith Laboratories LLC | $12.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.